Mycophenolic Acid Ophthalmic Formulation Oxygen Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mycophenolic acid is difficult to formulate as an ophthalmic solution due to its insolubility in cold water, leading to stability issues and reduced effectiveness over time, particularly in the presence of oxygen and light.
Innovation Solution
Ophthalmic formulations with mycophenolic acid or its salts are developed using an aqueous medium with a reduced level of dissolved oxygen, often below 3 ppm, and packaged in opaque containers with metal foil to minimize oxygen exposure, along with additional ingredients like antioxidants and viscosity modifiers to enhance stability and shelf-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mycophenolic acid is formulated in a conventional aqueous medium with normal dissolved oxygen levels, then the formulation process is simple, but the stability and shelf-life of the active ingredient deteriorates rapidly
Solution Approach 1:
The patent applies the inert atmosphere principle by reducing dissolved oxygen levels in the aqueous medium to less than 3 ppm through nitrogen purging and sealing. This creates an oxygen-depleted environment that prevents oxidation of mycophenolic acid, thereby maintaining stability and shelf-life without requiring complex chemical stabilizers or preservatives.
Solution Approach 2:
The patent changes the physical-chemical parameter of dissolved oxygen concentration from normal saturation levels to less than 3 ppm. This parameter change fundamentally alters the stability profile of the formulation, allowing mycophenolic acid to remain stable for extended periods without degradation.
2Reliability
If the aqueous medium contains normal levels of dissolved oxygen, then the formulation is easier to prepare, but the active ingredient degrades faster losing potency
Solution Approach 1:
The patent implements an inert atmosphere approach by purging the aqueous medium with nitrogen gas to reduce dissolved oxygen to less than 3 ppm. This prevents oxidative degradation of mycophenolic acid, ensuring potency retention over time. The process involves standard pharmaceutical manufacturing techniques for inert atmosphere preparation.
Solution Approach 2:
The patent applies preliminary action by reducing dissolved oxygen levels in the aqueous medium before adding mycophenolic acid or before final formulation completion. This pre-establishment of an oxygen-depleted environment ensures that the active ingredient is protected from the outset, preventing degradation rather than addressing it after occurrence.
3Reliability
If the container is transparent or allows oxygen permeability, then the packaging is simpler, but the formulation degrades due to oxygen and light exposure
Solution Approach 1:
The patent extends the inert atmosphere principle to the packaging level by using containers with oxygen barrier properties. The combination of nitrogen-purged formulation and oxygen-impermeable packaging creates a dual protection system that maintains oxygen-free conditions throughout the shelf-life of the product.
Solution Approach 2:
The patent employs packaging films or container walls with oxygen barrier properties to prevent oxygen permeation. This creates a physical barrier that maintains the oxygen-depleted environment inside the container, protecting the formulation during storage and transport.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations exhibit improved stability and shelf-life, with at least 90-95% of the active ingredient remaining after 12-24 months, effectively maintaining potency and reducing degradation from oxygen and light exposure.
Implementation Method 1
mycophenolic acid is difficult to formulate as an ophthalmic solution; it is almost insoluble in cold water... with a reduced level of dissolved oxygen relative to saturation level
Implementation Method 2
packaged in an opaque container or pouch including a metal foil for reducing oxygen permeability through the container or pouch
Data Source
AI summary
Ophthalmic formulations including mycophenolic acid or salt thereof in an aqueous medium having a reduced level of dissolved oxygen and processes for making such formulations and using such formulations are disclosed.